166Ho and 90Y labeled 6D2 monoclonal antibody for targeted radiotherapy of melanoma: Comparison with 188Re radiolabel |
| |
| Institution: | 1. Department of Chemistry, Hunter College of the City University of New York, 695 Park Avenue, New York, NY 10065, USA;2. Albert Einstein College of Medicine, Bronx, NY, USA;3. Missouri University Research Reactor, Columbia, MO, 65211 USA;1. Department of Chemistry, Hunter College of the City University of New York, 695 Park Avenue, New York, NY 10065, USA;2. Albert Einstein College of Medicine, Bronx, NY, USA;3. Missouri University Research Reactor, Columbia, MO, 65211 USA;1. Department of Medical Imaging, University of Arizona, Tucson, AZ, USA;2. Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA;3. AmProtein Cooperation, San Gabriel, CA, USA;1. Molecular Imaging and Radiochemistry, Nuclear Medicine Clinic, Friedrich-Alexander University, Schwabachanlage 6, D-91054 Erlangen, Germany;2. Department of Chemistry and Pharmacy, Emil Fischer Center, Friedrich-Alexander University, Schuhstrasse 19, D-91052 Erlangen, Germany;1. Vascular Biotechnology Laboratory, Baker IDI, Melbourne, Australia;2. Atherothrombosis and Vascular Biology Laboratory, Baker IDI, Melbourne, Australia;3. Departments of Nuclear Medicine and Centre for PET, Austin Hospital, Melbourne, Australia;4. Department of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Australia;5. Ludwig Institute for Cancer Research, Austin Hospital, Melbourne, Australia;6. The Florey Institute of Neuroscience and Mental Health, Austin Hospital, Melbourne, Australia;7. Central Clinical School, Monash University, Melbourne, Australia |
| |
| Abstract: | IntroductionAn approach to radioimmunotherapy (RIT) of metastatic melanoma is the targeting of melanin pigment with monoclonal antibodies (mAbs) to melanin radiolabeled with therapeutic radionuclides. The proof of principle experiments were performed using a melanin-binding antibody 6D2 of IgM isotype radiolabeled with a β emitter 188Re and demonstrated the inhibition of tumor growth. In this study we investigated the efficacy of 6D2 antibody radiolabeled with two other longer lived β emitters 90Y and 166Ho in treatment of experimental melanoma, with the objective to find a possible correlation between the efficacy and half-life of the radioisotopes which possess high energy β (Emax > 1.5 MeV) emission properties.Methods6D2 was radiolabeled with longer lived β emitters 90Y and 166Ho in treatment of experimental melanoma in A2058 melanoma tumor-bearing nude mice. The immunoreactivity of the radiolabeled 6D2 mAb, its in vitro binding to the MNT1 human melanoma cells, the biodistribution and therapy in A2058 human melanoma bearing nude mice as well as dosimetry calculations were performed.ResultsWhen labeled with the longer lived 90Y radionuclide, the 6D2 mAb did not produce any therapeutic effect in tumor bearing mice while the reduction of the tumor growth by 166Ho-6D2 was very similar to the previously reported therapy results for 188Re-6D2. In addition, 166Ho-labeled mAb produced the therapeutic effect on the tumor without any toxic effects while the administration of the 90Y-labeled radioconjugate was toxic to mice with no appreciable anti-tumor effect.Conclusions166Ho-labeled mAb to melanin produced some therapeutic effect on the tumor without any toxic effects while the administration of the 90Y-labeled radioconjugate was toxic to mice with no appreciable anti-tumor effect. We concluded that the serum half-life of the 6D2 carrier antibody matched well the physical half-life of 166Ho to deliver the tumoricidal absorbed dose to the tumor. Further investigation of this radionuclide for RIT of melanoma is warranted. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
